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Synovial sarcoma (SS), an aggressive type of soft tissue tumor, occurs mostly in adolescents and young adults. The origin and
molecular mechanism of the development of SS remain only partially known. Over 90% of SS cases are characterized by the
t(X;18)(p11.2;q11.2) translocation, which results mainly in the formation of SS18-SSX1 or SS18-SSX2 fusion genes. In recent
years, several reports describing direct and indirect interactions of SS18-SSX1/SSX2 oncoproteins have been published. These
reports suggest that the fusion proteins particularly aﬀect the cell growth, cell proliferation, TP53 pathway, and chromatin
remodeling mechanisms, contributing to SS oncogenesis. Additional research eﬀorts are required to fully explore the protein-
protein interactions of SS18-SSX oncoproteins and the pathways that are regulated by these partnerships for the development of
eﬀective targeted therapy.
1.Introduction
Synovial sarcoma (SS) represents approximately 10% of soft
tissue sarcomas. SS is an aggressive type of tumor, which
originates mainly in the extremities but may occur at any
anatomic site. Approximately 50% of SS patients develop
metastases, which mainly occur in the lungs. Contrary to the
“synovialsarcoma”term,SShasnobiologicalorpathological
relation to synovium [1, 2]. SS is considered as a sarcoma of
unknown origin, but recent ﬁndings have pointed to either a
neural [3], myogenic [4], or multipotent mesenchymal stem
cell [5, 6]. SS occurs in patients at any age but mainly in
adolescents and young adults, and it occurs more commonly
in males. A single SS case in a human fetus has been re-
ported by Duband et al. [7]. Considering histology, SS is
eitherbiphasic ormonophasic. Biphasic SShasepithelial and
spindle cell components in varying proportions [1, 8–11].
The epithelial cells form glands with lumina or papillary
structures. The spindle cell component often exists as a mo-
nophasic SS, in which spindle cells typically form dense
cellular sheets or fascicles. Another rare variant of SS, which
is classiﬁed as poorly diﬀerentiated, is characterized by ovoid
or rounded small cells similar to cells in other small round
cell tumors. This histological type is associated with the
worstclinicaloutcome[1,11,12].Well-establishedimmuno-
histochemical markers of SS include epithelial membrane
antigen (EMA), transducin-like enhancer protein 1 (TLE1),
and cytokeratins (CK7, CK19 and pan-cytokeratin) [13–18].2 Sarcoma
Immunohistochemical analysis is especially important in the
diﬀerential diagnosis of monophasic and poorly diﬀerentiat-
ed SS. However, these markers are not speciﬁc enough, and
the ﬁnal SS diagnosis is currently frequently supported by
cytogenetic or molecular tests.
The ﬁrst description of t(X;18) and the report linking
SS with the nonrandom presence of t(X;18) were published
in 1986 [19, 20]. Since 1986, numerous studies have been
undertakentoinvestigatetheroleofthet(X;18)(p11.2;q11.2)
translocationinSSdevelopmentandmaintenance.Thechar-
acteristic fusion gene found in more than 90% of SS cases
involves the SS18 (previously known as SYT)g e n eo nc h r o -
mosome 18 and one of the SSX genes on the X chromosome
[9, 10, 21]. Nine SSX genes (SSX1-9) have been described,
and they are highly homologous. The nucleotide sequence
homology of these genes ranges from 87 to 96%, and the
amino acid sequence homology ranges from 73 to 92%. The
SSX gene family also includes 10 pseudogenes, all of which
are located on the X chromosome [22]. The SS18 protein,
SSX protein, and SS18-SSX fusion protein are localized in
nucleus [23, 24].
2. Function of SS18 andSSX Genes
SS18 is a ubiquitously expressed gene that encodes a 387-
amino acid protein. This protein has two functional do-
mains, and both domains are involved in the regulation of
transcription. The SNH domain at the N-terminus is lo-
calized between amino acid residues 20 and 73, and it is
likely involved in the inhibition of transcriptional activation.
The second domain is called the QPGY domain, and it is
rich in glutamine, proline, glycine, and tyrosine residues.
This domain is localized between amino acid residues 187
and 387, and it has been described as a transcriptional
activator (Figure 1). The ribonucleoprotein, SYT-interacting
protein/coactivator activator (SIP/CoAA), speciﬁcally binds
to the QPGY domain of SS18. SIP/CoAA is an RNA spli-
cing modulator and coactivator of transcription, which may
point to a hypothetical mechanism of transcriptional reg-
ulation by SS18 and the SS18-SSX fusion transcript [25,
26]. Furthermore, the SS18 protein interacts with P300 (a
transcriptional coactivator and histone acetyltransferase),
which results in the formation of a P300/SS18 complex
that regulates cell adhesion [27]. Accordingly, Kimura and
coworkers [28] suggested that SS18 may control the expres-
sion of P300. Moreover, SS18 has been shown to interact
with the following proteins: the leukemia-associated protein,
AF10 (also known as MLLT10) [29]; components of the
chromatin remodeling complex, including hBRM and BRG1
(also known as SMARCA2 and SMARCA4, resp.) [30, 31]
and the growth factor receptor-bound protein, GBR2 [32].
Using mouse cDNA assays for the systematic analysis of pro-
tein/protein interactions, Suzuki et al. [33] demonstrated
thatSS18interactswiththeH3.3Ahistone.Itoandcolleagues
[34] reported that the SS18 protein interacts with mSIN3A
(a component of histone deacetylase complex), resulting in
mSIN3A repression of transcriptional activity mediated by
SS18. Kato and coworkers [35] showed that SS18 associates
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Figure 1: Schematic diagram shows the domains structure of
SS18 and SSX proteins. The amino acid residues representing
the boundaries of selected domains are indicated. SNH-SS18 N-
terminal domain; QPGY-SS18 domain rich in glutamine, proline,
glycine, and tyrosine; KRAB-SSX Kr¨ uppel-associated box domain;
SSXRD-SSX transcriptional repression domain.
also with the human SNF/SWI complex, which is a chro-
matin remodeling factor. Moreover, SS18 has an important
role in embryonic development because it participates in the
regulation of cell motility and cytoskeletal organization [28].
Furthermore, SS18 aﬀects the expression of genes important
for placental development, such as peroxisome proliferator-
activated receptor-binding protein (PPARB)[ 36]. The SS18
protein may also have an essential role in epithelial morpho-
genesis [37].
The SSX1 and SSX2 genes encode proteins consisting
of 188 amino acid residues. The SSX genes are normal-
ly expressed in the testis and thyroid, and these genes are
also expressed in numerous types of human cancers includ-
ing melanoma [38–40], multiple myeloma [41, 42], non-
Hodgkin’s lymphoma [39], neuroblastoma [43], brain tum-
ors [39, 44], various carcinomas of diﬀerent origin [39, 45–
51], and several types of sarcomas (synovial sarcoma, osteo-
sarcoma, and malignant ﬁbrous histiocytoma) [39, 52–57].
SSX1-5 proteins, except for SSX3, are considered cancer-
testis antigens (CTAs) [39, 40, 48, 58].
SSX proteins have a Kr¨ uppel-associated box (KRAB)
domain with transcriptional repression activity in their N-
terminus. Moreover, SSX proteins possess a transcriptional
repressor domain (SSXRD) in their C-terminus (155–188
position), and this domain is also present in the SS18-
SSX fusion protein (Figure 1)[ 59]. Interestingly, Dimitriadis
et al. [60] reported a single SS case with an unusual fusion
transcript lacking the SSXRD domain, which may indicate a
more signiﬁcant role of the SS18 protein in SS18-SSX-asso-
ciated oncogenesis.
There have been several reports concerning the interac-
tions of the SSX proteins, predominantly with regulators of
transcription and polycomb group (PcG) proteins. Soulez
and colleagues [61] demonstrated that the SSX1 and SSX2
proteins colocalize with chromatin, and Kato et al. [35]r e -
ported that the C-terminal region of the SSX1 protein
binds to the core histones. Cronwright and coworkers [62]
reported that SSX1-9 proteins participate in cell migration,
indicating that these proteins may have an analogical role
in cancer metastasis. The interactions of the SSX proteinsSarcoma 3
Table 1: Interactors of SSX proteins.
Gene symbol Gene description Function Reference
SSX1
FUBP3 Far upstream element (FUSE) binding protein 3 Regulation of transcription [151]
BMI1 BMI1 polycomb ring ﬁnger oncogene PcG protein-transcriptional repressor [61]
RING1A Ring ﬁnger protein 1 PcG protein-transcriptional repressor [61]
LHX4 LIM homeobox 4 Transcription factor [152]
SSX2
BMI1 BMI1 polycomb ring ﬁnger oncogene PcG protein-transcriptional repressor [61]
RING1A Ring ﬁnger protein 1 PcG protein-transcriptional repressor [61]
RING1B
(RNF2)
Ring ﬁnger protein 2 PcG protein-transcriptional repressor [117]
RAB3IP RAB3A interacting protein (rabin3) Protein transport [63, 153]
SSX2IP Synovial sarcoma, X breakpoint 2 interacting protein Cell adhesion [63, 153]
SSX3
DDIT3
(CHOP)
DNA-damage-inducible transcript 3 Transcription factor [151]
ZBTB25 Zinc ﬁnger and BTB domain containing 25 Regulation of transcription [151]
ZBTB3 Zinc ﬁnger and BTB domain containing 3 Regulation of transcription [151]
PCBD2
Pterin-4 alpha-carbinolamine
dehydratase/dimerization cofactor of hepatocyte
nuclear factor 1 alpha (TCF1) 2
Regulation of transcription [151]
ZNF496 Zinc ﬁnger protein 496 Regulation of transcription [151]
ZSCAN1 Zinc ﬁnger and SCAN domain containing 1 Regulation of transcription [151]
SSX2IP Synovial sarcoma, X breakpoint 2 interacting protein Cell adhesion [63, 153]
SSX4
HIF1A Hypoxia inducible factor 1, alpha subunit Transcription factor [151, 153]
PAX9 Paired box 9 Transcription factor [151]
XBP1 X-box binding protein 1 Transcription factor [151]
LZTR1 Leucine-zipper-like transcription regulator 1 Transcription factor [151]
SSX5
NFE2 Nuclear factor (erythroid-derived 2), 45kDa Regulation of transcription [151]
PCBD2
Pterin-4 alpha-carbinolamine
dehydratase/dimerization cofactor of hepatocyte
nuclear factor 1 alpha (TCF1) 2
Regulation of transcription [151]
ZSCAN1 Zinc ﬁnger and SCAN domain containing 1 Regulation of transcription [151]
are summarized in Table 1. Interestingly, the RAB3IP and
SSX2IP proteins interact with the N-terminal moiety of the
SSX2 protein, which is not present in the SS18-SSX fusion
protein [63].
3. SS18-SSXFusionTypes inSynovialSarcoma
The SS18-SSX chimeric proteins consist of all but 8 C-
terminal amino acids of the SS18 protein and 78 C-terminal
amino acid residues of either the SSX1 or SSX2 protein [64].
The SS18-SSX1 translocation is observed in approximately
two-thirds of tumors, and the SS18-SSX2 v a r i a n ti sf o u n di n
the remaining cases [10, 65, 66]. In addition, rare cases of
SS18-SSX4 chimeric variants in SS have been described, but
these have been characterized by high breakpoint variability,
with a possible functional unpredictability as a consequence.
[67–69]. The rare SS cases lacking the classical SS18-SSX
fusion gene may represent tumors with unusual variant
transcripts, which failed to be detected using conventional
approaches [70].4 Sarcoma
The SS18-SSX1 fusion type is mostly associated with
biphasic SS and the SS18-SSX2 type strongly correlates with
monophasic histology [10, 65, 66, 71, 72]. Saito et al. [73]
demonstrated a potential mechanism of such diﬀerentiation
involving Snail and Slug—the repressors of E-cadherin
(CDH1)—which is a crucial determinant of the epithelial
phenotype. The loss of E-cadherin has an important role in
the epithelial to mesenchymal transition in cancer [74, 75].
The study of Saito and colleagues [73] shows that SS18-
SSX2 fusion protein interacts preferentially with Slug and
SS18-SSX1 fusion protein interacts preferentially with Snail,
which is the stronger repressor of the E-cadherin promoter.
These observations provide a simpliﬁed explanation for the
heterogeneity in the acquisition of epithelial characteristics
in SS carrying diﬀerent fusion types.
Both SS18 and SSX proteins lack DNA-binding domains.
The most likely mechanism of their function on both a
single and fusion protein level is based on the regulation of
transcription and on the direct or indirect protein/protein
interactions [8]. According to the individual eﬀects of the
SS18 and SSX proteins, the SS18-SSX fusion protein may
havebothtranscriptionalactivationandrepressionfunctions
[30].
It was long unknown if the presence of the SS18-SSX
fusion protein is the only prerequisite for SS formation. A
hypothesis has been proposed stating that SS may develop
as a result of a series of molecular interactions in which
the activity of the SS18-SSX oncoprotein is only a link in a
sequence of other events. To elucidate this possible mech-
anism, Haldar and coworkers [4] created a mouse model
of SS by introducing conditional expression of the SS18-
SSX2 fusion gene in myoblasts. The authors described tumor
development in mice that resembled human SS with regard
to histological appearance, immunohistochemistry, tran-
scriptional proﬁle, and SS18-SSX2 fusion gene expression in
tumor cells. Their ﬁndings supported the idea of SS18-SSX
translocation as a crucial factor in SS pathogenesis.
Ishida and colleagues [76] demonstrated that SS18-
SSX1 can form homooligomers via the QPGY domain simi-
larly to the SS18 protein [31]. Moreover, the SS18-SSX1
fusion protein can form heterooligomers with normal SS18
proteins. Based on these ﬁndings, a model of SS has been
proposed in which target genes controlled by SS18 homo-
oligomers are repressed by the dominant negative function
of the SS18-SSX1/SS18 heterooligomers [76].
Several groups have investigated the prognostic value of
the diﬀerent fusion types, with contradicting results. Some
studies reported more favorable outcomes in patients with
the SS18-SSX2 fusion type [10, 65, 71, 77–79], and others
failed to ﬁnd any signiﬁcant correlation between fusion type
and clinical outcome [66, 80, 81].
4. Possible MechanismsinSSTumorigenesis
Considering published studies, which present downstream
andintermediatetargetsofSS18-SSX1andSS18-SSX2fusion
oncoproteins, several molecular pathways in SS development
may be proposed. Among the possible mechanisms involved
in SS, especially the promotion of cell growth and prolifera-
tion, deregulation of the TP53 signaling pathway, and inter-
ference of chromatin remodeling should be taken into ac-
count.
There is also a single study suggesting that the SS-asso-
ciated fusion protein causes fundamental changes in the cel-
lular cytoskeleton architecture.
Figure 2 summarizes the possible inﬂuence of SS18-
SSX fusion proteins on described direct and indirect targets,
which may contribute to SS tumorigenesis.
5.SS18-SSXFusionProteinsAffect Cell
Growth and Proliferation
Several reports indicate cyclin D1, β-catenin, TP53 pathway
components, early growth response protein 1 (EGR1), and
insulin-like growth factor 2 (IGF2) together with its receptor
IGF-1R as the most important targets of SS18-SSX fusion
oncoproteins, involved in the regulation of cell growth and
proliferation.
5.1. Cyclin D1 and β-Catenin. A study conducted by Xie
and colleagues [82] focused on the inﬂuence of the SS18-
SSX1 and SS18-SSX2 fusion proteins on tumor-relevant
and growth-regulatory proteins, including cyclins A/D1/E,
cyclin-dependent kinases (CDKs), p27, and BCL-2( ap r o t o -
oncogene).BCL-2wasexpressedatahighlevelin association
with both fusion types. Speciﬁcally, SS18-SSX1 was asso-
ciated with the upregulated expression of cyclins A and D1,
and these observations were conﬁrmed by Peng et al. [83].
Upregulation of cyclin D1 has been also associated with
SS18-SSX2 fusion type in another study conducted by Xie
and colleagues [84]. They suggested that the SS18-SSX2 pro-
tein interferes with the ubiquitin-dependent degradation
pathway, which results in the upregulation of cyclin D1. An
association between the expression level of cyclin D1 and the
SS18-SSX2 fusion protein was also investigated by T¨ ornkvist
andcoworkers[85],whofoundthattheSS18-SSX2proteinis
responsibleforthemaintenanceofbothcyclinD1expression
and cell proliferation in the examined SS cell lines.
Pretto et al. [86] suggested that β-catenin is another
downstream target of the SS-associated fusion proteins,
however they tested only the SS18-SSX2 variant. β-catenin
is an adherent junction-associated protein which connects
cadherins to the cytoskeleton. Alternatively, when localized
in the nucleus, β-catenin is an essential eﬀector of the
WNT signaling pathway. The misregulation of β-catenin-
mediated signaling leads to the development of numerous
human malignancies [87]. Pretto et al. [86] demonstrated
that SS18-SSX2 stimulates β-catenin signaling in a P300-
dependent manner. The fusion transcript recruits β-catenin
to the nucleus, forming a transcriptionally active nuclear
complex. Furthermore, the inhibition of SS18-SSX2 expres-
sion contributes to the loss of the nuclear β-catenin signal
and a strong decrease of β-catenin signaling activity. These
ﬁndings suggest that SS18-SSX2 triggers tumor development
partially through the β-catenin signaling but it should be
further investigated whether SS18-SSX1 has the same eﬀect.Sarcoma 5
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Figure 2: Targets of SS18-SSX1/2 fusion oncoproteins involved in cell growth and proliferation, TP53 pathway, chromatin remodeling,
and cytoskeleton remodeling, which may contribute to synovial sarcoma tumorigenesis. COM1-candidate of metastasis protein 1; PcG-
polycomb group proteins; EGR-early growth response protein 1; mSIN3A-transcriptional regulator; HDAC-histone deacetylase complex;
hBRM/hSNF2α-chromatin remodeling complex; TP53-tumor protein p53; HDM2-Mdm2 p53 binding protein homolog (mouse); XRCC4-
X-rayrepaircomplementingdefectiverepairinChinesehamstercells4;IGF2-insulin-likegrowthfactor2;IGF-1R-insulin-likegrowthfactor
1 receptor; BCL-2-B-cell CLL/lymphoma 2. ∗Only COM1 and mSIN3A have been described to interact directly with SS18-SSX1/2 fusion
proteins.
Interestingly, Horvai and colleagues [88] associated the
activation of nuclear β-catenin with the upregulation of
cyclinD1bothinprimaryandmetastaticSStissuespecimens
with conﬁrmed t(X;18) translocation. A probable mecha-
nism for this upregulation engages β-catenin and the WNT
signaling pathway, which activate the transcription complex
involving TCF/LEF. As a result, β-catenin contributes to the
increased cyclin D1 level, which is characteristic of many
cancers. These ﬁndings agree with the study by Bozzi and
coworkers [89] who examined 17 cases of SS in children and
adolescents with the conﬁrmed SS18-SSX fusion (11 cases
withSS18-SSX1 and 6 cases with SS18-SSX2). They observed
nuclear β-catenin localization in monophasic SS specimens
and cyclin D1 overexpression in monophasic and biphasic SS
specimens.
5.2. TP53 Pathway. Xie et al. [90] applied the antisense
strategy to block the expression of the SS18-SSX2 fusion
gene in SS cells, and they reported that the expression
of X-ray repair complementing defective repair in Chinese
hamster cells 4 (XRCC4) is signiﬁcantly decreased in such
conditions. The unﬁxed DNA damage in SS may activate
the TP53 checkpoint pathway to induce growth arrest or
apoptosis. This experiment has been conducted only in one
SS cell line carrying SS18-SSX2 transcript, but two other
studies of D’Arcy and coworkers demonstrated that TP53 is
aﬀected in cell lines expressing both SS18-SSX1 and SS18-
SSX2. Firstly, they demonstrated that SS18-SSX1 promotes
TP53 ubiquitination and degradation by a mechanism
involving the HDM2 (Mdm2 p53 binding protein homolog
in mouse). The fusion protein inhibited autoubiquitination
and increased the half-life of HDM2, making it more stable
in cells [91]. A subsequent study conﬁrmed that TP53 is
speciﬁcally aﬀected by HDM2 also in SYO-1 cell line, derived
from biphasic SS and carrying SS18-SSX2, which presented
the increase of TP53 stability, activation of TP53 target
genes, growth arrest, and apoptosis upon treatment with
HDM2 antagonist [92]. Another observation [91] was that
SS18-SSX1 attenuates the TP53 response and changes the
expression levels of several TP53-regulated genes, such as
BBC3 (BCL2 binding component 3) and PMAIP1 (phorbol-
12-myristate-13-acetate-induced protein 1), but it does not
aﬀect the expression level of the p21WAF1/CIP1 (also known as
CDKN1A-cyclin-dependent kinase inhibitor 1A). However,
contradictory results have been published by Tsuda and
coworkers [93] who reported that SS18-SSX1 upregulates
p21WAF1/CIP1 protein in the manner independent of the
hBRM chromatin remodeling factor and TP53 but depen-
dent on the SP1/SP3 transcription factors.
5.3. EGR1. Lubieniecka and coworkers [94] reported that
the SS18-SSX2 fusion protein inhibits a cancer-related gene
EGR1 through repressive histone modiﬁcations and recruit-
ment of PcG proteins. EGR1 encodes a serum-inducible
zinc ﬁnger protein, which is crucial for cell proliferation,
diﬀerentiation and apoptosis. The same group demonstrated
that EGR1 is a target of the fusion protein but they only
examined two cell lines carrying SS18-SSX2 fusion variant.
No cell line expressing SS18-SSX1 fusion gene has been
included in the study. The downregulation of EGR1 in SS
hasalsobeenobservedincDNAmicroarrayexperiments[94,
95]. Moreover, Su et al. [96] demonstrated that EGR1 aﬀects
the expression of phosphatase and tensin homolog deleted in
chromosome 10 (PTEN) ,w h i c hi sat u m o rs u p p r e s s o rg e n e
and an important phosphatase that regulates the PI3K/AKT
survival pathway. Both EGR1 and PTEN have been reported6 Sarcoma
to be downregulated by the speciﬁc microRNA, miR-183,
and the elevated level of miR-183 has been observed in SS
and other tumor types [97]. These data suggest the impor-
tant role of the EGR1 and PTEN tumor suppressors in SS
oncogenesis.
5.4. IGF2 and IGF-1R. IGF2 is another target of the SS18-
SSX fusion proteins. Upregulation of this gene has been
associated with the expression of both SS18-SSX1 and
SS18-SSX2 fusion proteins [95, 98, 99]. Upregulation of
IGF2 is necessary for tumor formation in vivo and for the
proliferation of cultured SS cells [99, 100]. The antiapoptotic
and mitogenic function of IGF2 is mediated by IGF-1R, and
the expression of this receptor has been also demonstrated
in SS cell lines and tumor specimens bearing SS18-SSX1
and SS18-SSX2 fusion proteins [85, 100–102]. In addition,
Friedrichs et al. [100] reported that also AKT and p44/42
MAPK(elementsofIGF-1R-relatedsignalingpathways)were
activated in the analyzed tumor specimens. Although IGF2
has an important role in SS, the overexpression of IGF2 is
not exclusive to this sarcoma subtype. For example, several
expression proﬁling studies have demonstrated IGF2 overex-
pression as a characteristic feature of gastrointestinal stromal
tumors (GISTs) and rhabdomyosarcomas [103–106].
The cell proliferation regulator, candidate of metastasis 1
(COM1),also known as p8 or nuclear protein transcriptional
regulator 1 (NUPR1), and ERK1/ERK2 MAPK signaling
pathway components have been proposed as other possible
targets of SS18-SSX fusion proteins, involved in the cell
proliferation regulation. However, there are only single
reports describing their role in SS.
Ishida et al. [76] observed that both SS18-SSX1/2 fusion
oncoproteinsdirectlydownregulatetheexpressionofCOM1,
which is expressed at low level both in cell lines carrying
diﬀe r e n tt y p e so ft r a n s l o c a t i o n ,a sw e l la si nS St u m o rs p e c -
imens. The authors demonstrated also that the knockdown
of SS18-SSX2 results in a strong upregulation of COM1
expression, which reduces in vitro cell growth and colony
formation of SYO-1 cell line. Additionally, the restoration of
COM1expressioninducedapoptosis inthiscellline.Overall,
their results indicated that the maintenance of COM1
expression at a low level has an important role in SS growth.
Cai et al. [107] performed RNA interference experiments
targeting the 19-nucleotide sequence of SS18-SSX2 mRNA
in SYO-1 cells, demonstrating that downregulation of the
fusion gene inhibits cell proliferation and diminishes the
protein levels of ERK1, ERK2, p-ERK, and cyclin D1.
6. SS18-SSXFusion ProteinsAreInvolvedin
ChromatinRemodeling
PcG proteins, histone deacetylase complex (HDAC), and
hBRM/hSNF2α complex are the most important targets of
SS18-SSXfusiononcoproteinsinvolvedinchromatinremod-
eling.
6.1. Polycomb Group Proteins. PcG proteins are involved in
the repression of gene transcription through the modulation
ofchromatinstructure.Functionalderegulationofpolycomb
complexes has been previously demonstrated during cancer
progression. The polycomb complex is usually involved in
tumorigenesis as a result of its upregulation [108–110].
However,downregulationofthepolycombcomplexhasbeen
d e s c r i b e di ng e r mc e l lt u m o r s[ 111] and some breast tumors
[112].
According to the study of dos Santos and colleagues
[113], SSX2 and both SS18-SSX1/2 proteins colocalize with
PcG proteins. Speciﬁcally, co-localization of SS18-SSX1 and
SS18-SSX2 fusion proteins with RING1 proteins, SS18-SSX2
fusion proteins with HPC2 proteins, and SSX2 proteins with
RING1 proteins, BMI1 proteins and chromatin have been
reported. However, these colocalizations are not the result of
direct physical interactions. These ﬁndings were consistent
with a study by Soulez et al. [61] who demonstrated that
SSX1, SSX2, SS18-SSX1, and SS18-SSX2 proteins colocalize
with BMI1 and that SSX1, SSX2, and SS18-SSX2 proteins
colocalize with chromatin. Moreover, colocalization of SS18-
SSX2 fusion proteins with RING1 proteins has also been
observed. Yet, Western blot analysis did not conﬁrm the
direct interactions of these proteins [61]. Furthermore, poly-
comb deregulation by SS18-SSX fusion proteins has been
demonstrated in two other studies. Cironi and colleagues
[98] showed that the polycomb target genes appear to be
aﬀected by the expression of SS18-SSX1. Barco et al. [114]
reported that the SS18-SSX2 fusion protein modulates the
silencing activity of the polycomb repressive complex and
destabilizes BMI1 proteins, leading to the impairment of
polycomb-dependent histone H2A ubiquitination and reac-
tivation of the polycomb target genes.
6.2. Histone Deacetylase Complex (HDAC). Ito and col-
leagues[34]observedthatSS18andSS18-SSX1proteins(but
not SS18-SSX2 protein) can bind mSIN3A proteins, which
are a part of the histone deacetylase complex (HDAC).
HDAC aﬀects gene expression by acting on chromatin
through transcriptional factors, corepressors and methyl-
CpG binding proteins. Based on these ﬁndings, Ito et al.
[115] further investigated the impact of the histone deacetyl-
ase inhibitor, FK228, on SS growth both in vitro and in vivo.
They examined cell lines carrying both the SS18-SSX1 and
SS18-SSX2 fusion proteins. As a result of treatment with
the FK228 inhibitor, the growth of cultured SS cells and SS
xenografts in mice was signiﬁcantly reduced. Also tumor
weight and tumor density decreased after FK228 treatment.
Remarkably, cells carrying the SS18-SSX2 fusion protein
were more sensitive than those carrying the SS18-SSX1 one.
6.3. hBRM/hSNF2α Complex. Nagai and coworkers [116]
assessed the transforming activity of the SS18-SSX1 fusion
protein, and they correlated the growth rate of the cells
with the expression level of the SS18, SSX1,a n dSS18-SSX1
genes introduced into three independent clones of 3Y1 rat
ﬁbroblast cell lines. 3Y1 cells expressing SS18-SSX2 fusion
genewerenotincludedinthestudy.Theresearchersreported
that the human SS18-SSX1 fusion gene imposed the highest
growth rate among the genes tested. Furthermore, theySarcoma 7
established the association between the SS18-SSX1 protein
and the chromatin remodeling complex, hBRM/hSNF2α.
They proposed that this complex has an essential role in
SS18-SSX1-induced transformation, suggesting that it may
downregulate the deleted in colorectal carcinoma (DCC)
tumor suppressor.
7.SS18-SSX2 FusionProteinand Its Role in
Cytoskeleton Remodeling
Barco et al. [117] presented another possible mechanism
of carcinogenesis triggered by the SS18-SSX2 fusion onco-
protein. They reported that SS18-SSX2 stabilizes the micro-
tubule network and stimulates the expression and activa-
tion of EPH/ephrin pathway components. The EPH/ephrin
system is involved in the regulation of cytoarchitecture
and determination of cell position during development and
tissue regeneration. In tumors, the EPH/ephrin system has
been linked to angiogenesis, loss of cell adhesion, and
enhanced migration. Overall, the study suggested that the
SS18-SSX2 fusion protein causes fundamental changes in the
cellular cytoskeleton architecture; however, this mechanism
has not been investigated in cells carrying SS18-SSX1 fusion
transcript.
8. Discussion
8.1. Development of Targeted Therapy for Synovial Sarcoma.
Based on the assumption that cancer-related pathways and
proteins that are upregulated in SS may serve as possible
therapeutic targets, a few important directions should be
considered. Bozzi and colleagues [89] showed that EGFR
and platelet-derived growth factor receptors (PDGFRA and
PDGFRB)areupregulatedinSSwithsubsequentPI3K/AKT/
mTOR pathway activation. Consecutive reports by Dobashi
et al. [118] and Friedrichs et al. [119] also demonstrated
the activation of the PI3K/AKT/mTOR pathway in SS. These
reports suggest that inhibitors of the PI3K/AKT/mTOR
pathway may be used for a potential therapy of SS through
the repression of multiple upstream targets of this pathway.
Several other studies have conﬁrmed the upregulation of the
receptor tyrosine kinases EGFR, PDGFRA and PDGFRB in
SS that can be targeted by speciﬁc small molecule inhibitors
[120–127]. HER-2/neu, BCL-2, and ﬁbroblast growth factor
receptor 2 (FGFR2) are among other proteins considered as
potentialtargetsinSS[6,17,82,122,128].Additionally,IGF-
1R may be a suitable target in SS therapy, and therapeutic
antibodies against IGF-1R and small molecules inhibiting
the tyrosine kinase activity of IGF-1R have been already
developed [85, 101, 129].
Since the presence of SS18-SSX fusion proteins is a
proven prerequisite for SS oncogenesis, a detailed insight
into the mechanisms of their interactions may contribute
to the development of targeted therapies, which are still
unavailable for SS patients. Several direct eﬀectors of SS18-
SSX fusion proteins in SS have been already conﬁrmed but
they have not yet been examined as potential therapeutic
targets. Thus, it may be reasonable to undertake new studies
with the following aims: (1) to accurately characterize the
nature of these interactions, including the domains or
amino acid residues involved; (2) to screen small molecule
libraries to detect potential molecules that interrupt selected
interactions; (3) to test selected small molecules in synovial
sarcoma animal models; (4) to transfer these results to
clinical trials. Such strategy is reasonable especially in the
light of recent ﬁndings made by Erkizan and coworkers
[130] who identiﬁed a small molecule inhibitor of EWS-FLI1
fusion transcript interaction with RNA helicase A (RHA),
which is important in the oncogenesis of Ewing’s sarcoma
family tumors (ESFTs).
Moreover,theSS18andSSXproteinshavebeendescribed
to individually interact with several important regulators of
transcription. Hence,it is rational to test in the futurestudies
whethertheSS18-SSXfusionproteinsalsointeractwiththese
molecules. Among proteins that colocalize both with SSX
and SS18-SSX are PcG proteins, which appear to be an inter-
esting targetin synovialsarcoma therapy. Theimportant role
of PcG proteins in oncogenesis has been already extensively
reviewed [131, 132] and some recent publications support
their use as molecular targets in anticancer therapy. Dimri
and coworkers [133] showed that the aberrant expression
of PcG protein enhancer of zeste homologue 2 (EZH2) can
be suppressed by dietary omega-3 polyunsaturated fatty
acids (PUFAs), leading to decrease in the invasion potential
of breast cancer cells. Another study published by Kemp
and colleagues [134] demonstrated that pharmacological
inhibition of polycomb repressor complex-2 (PRC-2) is a
successfultherapeuticstrategyinmalignantpleuralmesothe-
lioma. Even though RING1 and BMI1 proteins which
colocalize with SSX and SS18-SSX are the components of
another polycomb repressor complex-1 (PRC-1), the above-
mentioned results provide rationale to test the inﬂuence of
PRC-1 inhibition on the synovial sarcoma oncogenesis.
As of yet, the completed clinical trials investigating the
role of selected targets in SS did not point to any successful
therapeuticstrategy.AphaseIIstudyconductedbytheEuro-
pean Organization for Research and Treatment of Cancer
(EORTC)Soft Tissue and Sarcoma Group demonstrated that
geﬁtinib treatment speciﬁcally targeting EGFR failed in SS
patients [135]. The reports about EGFR upregulation in SS
have not indicated any direct interaction or association with
the SS18-SSX1 or SS18-SSX2 fusion proteins which might
explain why inhibition of EGFR pathway was not successful
in SS treatment [122, 126]. However, geﬁtinib was the only
EGFR inhibitor examined thus far in SS and the eﬃca-
cy of other small molecule EGFR inhibitors remain to be
explored. Similarly in reference to the upregulation of
PDGFRA/B in SS, a phase II study assessing imatinib eﬃ-
c a c yi n1 0s a r c o m as u b t y p e sd e t e r m i n e dt h a ti ti sn o ta n
active agent in SS [136]. Nonetheless, another phase Ib/II
clinical trial has been undertaken to examine the eﬃcacy
of imatinib in combination with mTOR inhibitor everoli-
mus in SS patients (NCT01281865). Another ongoing phase
II study including SS patients aims to evaluate the combined
use of mTOR inhibitor temsirolimus with IGF-1R monoclo-
nal antibody cixutumumab (NCT01016015). Furthermore,
there are two phase II clinical trials in progress includ- ing SS8 Sarcoma
patients,whichexaminethetreatmentwithHDACinhibitors
(NCT01112384 and NCT01136499). Hopefully the results of
these trials will shed more light on possible directions in SS
targeted therapy.
8.2. Hypothetical Network of Interactions. Interestingly, there
have been several reports demonstrating interactions bet-
weenthevariousgenesandproteinsmentionedinthisreview
without reference to SS development or SS maintenance.
Many of the SS18-SSX1/2 targets, such as COM1, HDM2,
cyclin D1, and EGR1, have been described to interact with
P300 proteins [137–141]. In addition, HDM2 may interact
with p21WAF1/CIP1 and may associate with chromatin [142].
Furthermore, the nuclear epidermal growth factor receptor
(EGFR) participates in cyclin D1 transcription [143], and
cyclins D1 and A bind to p21WAF1/CIP1 [144]. Tsuda et al. [93]
described that the upregulation of p21WAF1/CIP1 is dependent
on the SP1/SP3 transcription factors. Importantly, the SP1
transcription factor interacts with EGR1, HDM2 and TP53,
whichareallimplicatedinSStumorigenesisviaSS18-SSX1/2
fusion proteins [145–150]. Further studies of these potential
interactions in the context of SS should be conducted; they
may provide a broader perspective on oncogenic pathways in
SS.
8.3. SS18-SSX1 versus SS18-SSX2. As far as pathways involv-
ing cell growth, cell proliferation, TP53, and chromatin
remodeling are concerned, it has been shown that both the
SS18-SSX1 and SS18-SSX2 fusion proteins may interfere
withthem,butoftenthroughdistinctmolecularinteractions.
The cytoskeleton remodeling mechanism has been examined
exclusively for the SS18-SSX2 fusion type. It should be taken
into consideration that there has been still a relatively small
number of studies conducted to determine downstream and
intermediate targets of SS18-SSX1/2 fusion oncoproteins.
Probably many of their interactions and direct eﬀects remain
unknown.
Notably, it is important to distinguish between the SS18-
SSX1 and SS18-SSX2 oncoproteins while studying the role
of the fusion transcript in SS formation. Both by functional
and expression proﬁling studies, it has been shown that these
proteins may have distinct molecular activities even though
their sequences are highly homologous and they induce
tumors with similar pathological features. Inagaki et al.
[77] compared the impact of SS18-SSX1 and SS18-SSX2 fu-
sion types on the expression level of several tumor cell pro-
liferation-associated genes and other tumor-related patho-
l o g i c a lp a r a m e t e r si nS Sp r i m a r yt u m o rs p e c i m e n s .A sc o m -
paredtotheSS18-SSX2fusionprotein, theSS18-SSX1fusion
protein is related to higher mitotic rate and higher prolif-
eration index as measured by Ki-67 staining. In turn, Fer-
nebro and coworkers [11] conducted gene expression pro-
ﬁling studies to determine gene expression diﬀerences
between SS18-SSX1 and SS18-SSX2 SS variants. Among the
upregulated genes associated with the SS18-SSX1 fusion
protein they listed genes involved in oncogenesis, such as
TCF7, ZIC2, IGFBP3, SPAG7, AGRN, VIL2, AXL, RALGDS,
and CDC2LI, in addition to genes encoding metalloth-
ioneins, histones and G protein-coupled receptors. Genes
characteristically overexpressed in SS with the SS18-SSX2
fusion type include FOXC1, GAS1,a n dNCAM1.
BecauseSSspecimenscarryingdiﬀerentSS18-SSXfusion
proteins may have distinct molecular characteristics, it seems
inappropriate to formulate conclusions about the function
of the SS18-SSX fusion protein based on the results obtained
only for one fusion type. Moreover, some reports describe
a general role of the SS18-SSX fusion protein even though
the actual fusion type was not deﬁned or may have been
only presumed from the SS cell line used in the particular
experiment.InthesearchforthefunctionsofSS18-SSX1and
SS18-SSX2, it is necessary to conduct studies that include cell
linesortumorspecimengroupswithdiﬀerenttypesoffusion
proteins, allowing their possible heterogeneous molecular
functions to be recognized.
Current state of the SS research indicates that SS18-
SSX fusion proteins deregulate mostly cell growth, cell pro-
liferation, TP53 pathway, and chromatin remodeling mech-
anisms. Several molecules involved in these pathways occur
to be emerging therapeutic targets, especially those directly
interactingwithSS-associatedfusionproteins.Itiscrucialfor
the prospective clinical trials to select potential therapeutic
targets on the basis of functional studies that explore the
critical drivers of SS oncogenesis. However, many aspects of
SS tumorigenesis and network of SS18-SSX fusion proteins
interactions remain to be elucidated.
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